共 48 条
- [31] A Phase 2 Randomized Clinical Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda Monotherapy in Patients with Chronic Hepatitis Delta Virus Infection. Interim Results From the LIMT HDV StudyHEPATOLOGY, 2017, 66 : 496A - 496AHamid, Saeed S.Etzion, OhadLurie, YoavBader, NimrahYardeni, DavidChanna, Saleh M.Mawani, MinazParkash, OmMartins, Eduardo B.Gane, Edward J.
- [32] Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design studyJOURNAL OF HEPATOLOGY, 2022, 77 : S4 - S5Wedemeyer, HeinerAleman, SooBrunetto, MauriziaBlank, AntjeAndreone, PietroBogomolov, PavelChulanov, VladimirMamonova, NinaGeyvandova, NataliaViacheslav, MorozovSagalova, OlgaStepanova, TatyanaManuilov, DmitrySuri, VithikaAn, QiFlaherty, John F.Osinusi, AnuZur Wiesch, Julian SchulzeCornberg, MarkusZeuzem, StefanLampertico, Pietro
- [33] EFFICACY AND SAFETY OF BULEVIRTIDE MONOTHERAPY GIVEN AT 2 MG OR 10 MG DOSE LEVEL ONCE DAILY FOR TREATMENT OF CHRONIC HEPATITIS DELTA: WEEK 48 PRIMARY ENDPOINT RESULTS FROM A PHASE 3 RANDOMIZED, MULTICENTER, PARALLEL-DESIGN STUDYGASTROENTEROLOGY, 2023, 164 (06) : S1367 - S1368Wedemeyer, HeinerAleman, SooBrunetto, Maurizia R.Blank, AntjeAndreone, PietroBogomolov, PavelChulanov, VladimirMamonova, NinaGeyvandova, NataliaMorozov, ViacheslavSagalova, OlgaStepanova, Tatyana V.Manuilov, DmitryShah, VickiSuri, VithikaAn, QiFlaherty, John F.Osinusi, Anuzur Wiesch, Julian SchulzeCornberg, MarkusZeuzem, StefanLampertico, Pietro
- [34] Continuing Besifovir Dipivoxil Maleate versus switching from Tenofovir Disoproxil Fumarate for treatment of chronic hepatitis B: 96 weeks results of phase 3 trialJOURNAL OF HEPATOLOGY, 2018, 68 : S87 - S88Ahn, S. H.Kim, W.Yim, H. J.Yang, J. M.Jang, J. Y.Kweon, Y. O.Cho, Y. K.Kim, Y. J.Hong, G. Y.Kim, D. J.Um, S. H.Sohn, J. H.Lee, J-W.Park, S. J.Lee, B. S.Kim, J. H.Kim, H. S.Yoon, S. K.Kim, M. Y.Lee, K. S.Lim, Y. -S.Lee, W. S.Han, K-H.
- [35] 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, openlabel, randomised, multicentre study MYR204JOURNAL OF HEPATOLOGY, 2024, 80 : S1 - S2Asselah, TarikChulanov, VladimirLampertico, PietroWedemeyer, HeinerStreinu-Cercel, AdrianPantea, VictorLazar, StefanGherlan, George SebastianBogomolov, PavelStepanova, TatyanaMorozov, ViacheslavSyutkin, VladimirSagalova, OlgaManuilov, DmitryMercier, Renee-ClaudeYe, LeiChee, Grace M.Da, Ben L.Lau, Audrey H.Osinusi, AnuBourliere, MarcRatziu, VladPol, StanislasHilleret, Marie-NoelleZoulim, Fabien
- [36] No amino acid substitution in HBV PreS1, HDAg, or NTCP associated with suboptimal response to bulevirtide in combination with pegylated interferon alfa-2a treatment in participants with chronic hepatitis delta: results from MYR204 a phase 2b studyJOURNAL OF HEPATOLOGY, 2024, 80 : S737 - S738Liu, YangChang, SilviaXu, SiminMartin, RossAeschbacher, ThomasManhas, SavrinaMateo, RobertoMay, LindseyHan, DongYazdi, TahminehMarceau, CalebRichards, ChristopherHo, Pui YanLi, ChunfengMartinez, ClarissaPeinovich, NadineLopez, AndrewManuilov, DmitryMercier, Renee-ClaudeLau, Audrey H.Asselah, TarikZoulim, FabienMaiorova, EvgueniaMo, Hongmei
- [37] End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infectionJOURNAL OF HEPATOLOGY, 2019, 70 (01) : E32 - E32Etzion, OhadHamid, Saeed SadiqLurie, YoavGane, EdwardBader, NimrahYardeni, DavidNevo-Shor, A.Channa, S. M.Mawani, MinazParkash, OmYang, KyungheeLongo, DianeGish, Robert G.Glenn, JeffreyApelian, David
- [38] RG-101 IN COMBINATION WITH 4 WEEKS OF ORAL DIRECT ACTING ANTIVIRAL THERAPY ACHIEVES HIGH VIROLOGIC RESPONSE RATES IN TREATMENT NAIVE GENOTYPE 1 AND 4 CHRONIC HEPATITIS C PATIENTS: INTERIM RESULTS FROM A RANDOMISED, MULTI-CENTER, PHASE 2 STUDYJOURNAL OF HEPATOLOGY, 2016, 64 : S159 - S159Horvath, G.Papatheodoridis, G.Fabri, M.Makara, M.Grint, P.Huang, M.Blem, J.Lombardi, E.
- [39] A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis - end of study results from the LOWR HDV-3 studyJOURNAL OF HEPATOLOGY, 2017, 66 (01) : S101 - S102Koh, C.Surana, P.Han, T.Fryzek, N.Kapuria, D.Etzion, O.Takyar, V.Rotman, Y.Canales, R.Dahari, H.Yurdaydin, C.Glenn, J.Heller, T.
- [40] Safety, Pharmacokinetics and Anti-Viral Efficacy of Novel Core Protein Allosteric Modifier GLS4 in Patients with Chronic Hepatitis B: Interim Results from a 48 Weeks Phase 2a StudyHEPATOLOGY, 2018, 68 (06) : 1454A - 1455AZhang, HongZhu, XiaoxueChen, HongLi, XiaojiaoHu, YueWu, MinLi, CuiyunLuo, LinZhang, YingjunDing, Hua YanNiu, JunqiLiu, YanHe, QingweiChen, YunfuRen, QingyunGu, BaohuaJing, Li